Interesting concept, but it will never happen with the amount of pull (and money) drug companies have:
Limited-time drug licensure would furnish incentives to ensure that all new drugs are properly scrutinized. Companies would need to formulate post-marketing surveillance plans as well as promotional plans when a drug is approved. The FDA would be subject to firm deadlines in reviewing post-marketing information, because prescribers and patients would be relying upon a seamless system of licensure renewal in the absence of negative information.
Related posts:
- How should the FDA regulate the social media advertising of drugs?
- Should patients be paid to promote drugs?
- How pharmaceuticals are maximizing profits in anticipation of competition from generics
- Death of the drug rep, and who will take their place?
- Medicare covers more cancer drugs, did they cave in to the pharmaceutical lobby?
- "Survivor" doctor busted for drugs
- California’s universal health plan proposal
KevinMD.com on Facebook
Comments on this entry are closed.